Significant up-regulation of lncRNAs in neuromyelitis optica spectrum disorder.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 10 2023
31 10 2023
Historique:
received:
28
07
2023
accepted:
19
10
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Neuromyelitis optica spectrum disorder (NMOSD) is an immune-related demyelinating defect. Long non-coding RNAs (lncRNAs) might influence the pathobiology and progression of NMOSD. The current study assessed expression level of NEAT1, PANDAR, MEG3 and TUG1 lncRNAs in the peripheral blood of NMOSD patients compared with healthy individuals. All mentioned lncRNAs were shown to be over-expressed in total NMOSD cases, male NMOSD cases and female NMOSD cases compared with the matching control subgroups. MEG3 had the most robust over-expression in patients subgroups compared with normal subjects. There was no noteworthy difference in the expression of any of lncRNAs between female and male patients. MEG3 had an ideal performance in the differentiation of NMOSD cases from healthy persons (Sensitivity and specificity values = 100%). Other lncRNAs could also efficiently separate NMOSD cases from control subjects (AUC values = 0.97, 0.89 and 0.88 for PANDAR, NEAT1 and TUG1, respectively). Cumulatively, NEAT1, PANDAR, MEG3 and TUG1 lncRNAs can be considered as appropriate disease markers for NMOSD.
Identifiants
pubmed: 37907501
doi: 10.1038/s41598-023-45457-w
pii: 10.1038/s41598-023-45457-w
pmc: PMC10618193
doi:
Substances chimiques
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18692Informations de copyright
© 2023. The Author(s).
Références
Genes Immun. 2021 Dec;22(7-8):322-326
pubmed: 34782775
Mol Neurobiol. 2017 Apr;54(3):2201-2208
pubmed: 26941100
Front Genet. 2021 Jun 16;12:679097
pubmed: 34220951
Cell Death Dis. 2014 May 22;5:e1243
pubmed: 24853421
J Cell Mol Med. 2020 Jul;24(13):7460-7469
pubmed: 32436312
Cells. 2020 Feb 25;9(3):
pubmed: 32106407
Biomed Pharmacother. 2019 Oct;118:109129
pubmed: 31326791
Biomolecules. 2022 Apr 17;12(4):
pubmed: 35454180
J Mol Neurosci. 2019 Feb;67(2):276-281
pubmed: 30565169
J Mol Neurosci. 2020 Oct;70(10):1533-1540
pubmed: 32578033
Neural Regen Res. 2016 Mar;11(3):410-1
pubmed: 27127473
Neurol Sci. 2023 Oct;44(10):3647-3657
pubmed: 37191810
J Immunol Res. 2015;2015:848790
pubmed: 26090502
J Mol Neurosci. 2016 May;59(1):18-23
pubmed: 27034068
Front Immunol. 2021 Oct 05;12:737673
pubmed: 34675927
J Neuroinflammation. 2023 Apr 3;20(1):89
pubmed: 37013543
Open Access Maced J Med Sci. 2019 Oct 14;7(20):3433-3436
pubmed: 32002068
Front Immunol. 2023 May 16;14:1135540
pubmed: 37261349
CNS Neurol Disord Drug Targets. 2020;19(4):306-317
pubmed: 32552656
Sci Rep. 2021 Aug 9;11(1):16061
pubmed: 34373511
Mult Scler Relat Disord. 2022 Jul;63:103825
pubmed: 35537276
Sci Signal. 2018 Jun 26;11(536):
pubmed: 29945883
Mult Scler Relat Disord. 2023 Aug;76:104801
pubmed: 37315471
Wiley Interdiscip Rev RNA. 2016 Jan-Feb;7(1):129-43
pubmed: 26667656
J Immunol Res. 2022 Feb 21;2022:9557859
pubmed: 35237695
Mult Scler Relat Disord. 2018 Oct;25:219-226
pubmed: 30114626
Rev Neurol (Paris). 2023 Jun;179(6):533-547
pubmed: 36781321
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118
pubmed: 33353982
CNS Neurosci Ther. 2022 Jul;28(7):981-991
pubmed: 35426485
Nat Commun. 2019 Apr 2;10(1):1495
pubmed: 30940803
Int Immunopharmacol. 2022 Aug;109:108899
pubmed: 35689955